Key Highlights
- $1.6 million grant awarded by the Bill & Melinda Gates Foundation to Surf Bio, Inc.
- Focus on increasing thermostability and deliverability of monoclonal antibodies in low- and middle-income countries.
- Potential to eliminate refrigeration and enable subcutaneous administration of biologics.
Source: Business Wire
Notable Quote
- “Surf Bio’s stabilization platform enables pharmaceutical formulations and delivery in resource-constrained settings that are not currently possible with today’s technologies,” – Bryan Mazlish, Co-founder and CEO at Surf Bio
SoHC's Take
The recent funding by the Bill & Melinda Gates Foundation to Surf Bio underscores a significant advancement in biopharmaceutical technology, particularly for regions that face logistical challenges in medicine preservation and administration. Surf Bio’s innovative polymer technology not only aims to stabilize drugs but also facilitates easier and potentially more effective drug delivery systems. This grant not only supports ongoing research but also highlights the critical need for accessible healthcare solutions in underprivileged areas, promoting a shift towards more sustainable and broad-reaching health interventions.
